

Amendment to the Claims

Listing of the claims

1.26. (Canceled)

27. (Original) A vaccine composition comprising: (a) at least one peptide antigen; and (b) an expression vector comprising a polynucleotide encoding at least one cytokine selected from the group consisting of CD40 ligand (CD40L), tumor-necrosis factor-related activation-induced cytokine (TRANCE) and Flt3 ligand (flt-3L).

28.-29 (Canceled)

30. (Original) The vaccine composition according to claim 27, wherein the polynucleotide and/or the at least one peptide antigen is coated onto a core carrier.

31.-32. (Canceled)

33. (Original) A method for eliciting an immune response in a vertebrate subject, said method comprising: (a) providing a vaccine composition according to claim 27; and (b) administering the composition to the subject in an amount sufficient to elicit an immune response.

34.-37. (Canceled)

38. (Original) A method for eliciting an immune response in a vertebrate subject, said method comprising: (a) providing a vaccine composition according to claim 30; and (b) administering the composition of step (a) to the subject using a particle-mediated delivery technique.

39. (Original) The method of claim 38, wherein step (b) is repeated to provide a prime and a booster administration.

40.-41. (Canceled)

42. (New) The vaccine composition of claim 27, wherein the antigen is encoded by a polynucleotide, which is coated onto the core carrier.

43. (New) A vaccine composition comprising: (a) an expression vector comprising a polynucleotide encoding at least one peptide antigen; and (b) an expression vector comprising a polynucleotide encoding tumor-necrosis factor-related activation-induced cytokine (TRANCE).

44. (New) The vaccine composition of claim 43, wherein both of the vectors are coated onto a core carrier.

45. (New) A method for eliciting an immune response in a vertebrate subject, said method comprising: (a) providing a vaccine composition according to claim 43; and (b) administering the composition to the subject in an amount sufficient to elicit an immune response.

46. (New) A method for eliciting an immune response in a vertebrate subject, said method comprising: (a) providing a vaccine composition according to claim 44; and (b) administering the composition of step (a) to the subject using a particle-mediated delivery technique.

47. (New) The method of claim 46, wherein step (b) is repeated to provide a prime and a booster administration.